

## SIKKIM MANIPAL INSTITUTE OF MEDICAL SCIENCES SMIMS INSTITUTION ETHICS COMMITTEE



## APPLICATION FORM FOR RESEARCH PROJECT PROPOSAL REVIEW

FOR OFFICE USE	ONLY: PROPOSAL ID NO:			
Review type	New Revised	Received	Ion D D M M	YYYY
Review class	Exempted Expedited Full	Review b	y IHREC	IAEEC
Review group	IEC Ad-hoc members	Review o	n DDMM	YYYY
Signature of Memb	er Secretary			
1	TO BE FILLED IN CAPITAL LETTERS B	Y PRINCIF	PAL INVESTIGATOR	
PROPOSAL T	TTLE:			
Investigators	Name, Designation& Qualifications	Ad	dress / Tel & Fax Nos. Email ID	Signature
Principal Investigator				
Co- Investigators				
Curriculum Vita	ae of Investigators:	1		
SPONSOR IN	FORMATION			
1. Indian	a. Government Central	Sta	te Instituti	ional
	b. Private			
2. International	Government Private	UN	agencies	
3. Industry	National Multinationa	al		
Contact addres	ss of the Sponsor:			

Total Budget:

## **PROJECT DETAILS:** Epidemiological 1. Type of Study **Basic Sciences Animal Studies** Clinical Behavioral Single Centre Multicentric Revised Status of Review New : Drug/Vaccines/Device/Herbal remedies/Others 3. **Clinical Trials** i. Does the study involve use of: **Devices Vaccines** Drug ISM / ASM\* Any other NA \* ISM - Indian Systems of Medicine / ASM - Alternate Systems of Medicine ii. Is it approved and marketed in: UK & Europe **USA** India Other Countries, specify iii. Does it involve a change in use, dosage, route of administration? Yes No If Yes, whether DCGI's / any other regulatory authority's Yes No permission is obtained? If Yes, Date of Permission iv. Is it an Investigational New Drug Yes No If Yes, Investigational New Drug No: a. Investigator's Brochure submitted Yes No b. In vitro studies data Yes No c. Preclinical studies done Yes No Phase I Phase II Phase III Phase IV d. Clinical Study is Yes No e. Are you aware if this study / similar study is being done elsewhere? If Yes, attach details.

4. Brief description of the proposal:

ο.	i. Number of subjects (sample size) :		
	ii. Duration of the study :		
	iii. Will study subjects from both sexes be recruited	Yes	No
	iv. Inclusion / Exclusion criteria given	Yes	No
	v. Type of subjects	Volunteers	Patients
	vi. Vulnerable subjects	Yes	No
	Pregnant women Children	Elderly	Fetus
	Illiterate Handicapped	Terminally ill	Seriously ill
	Mentally challenged Economically & Soc	ially backward	Any other
	vii. Special group subjects		
	Captives Institutionalized	Employees	Students
	Nurses Armed forces	Dependant staff	Any other
<b>5</b> .	Privacy and Confidentiality:  i. Study involves Direct identifiers	Indirect identifiers / coded	Complete anonymity / delinked
	ii. Confidential handling of data by staff	Yes	No
7.	Use of Biological / Hazardous materials		
	i. Use of fetal tissue or abortus	Yes	No
	ii. Use of organs or body fluids	Yes	No
	iii. Use of recombinant / gene therapy	Yes	No
	If Yes, has Department of Biotechnology (DBT) approval for rDNA products been obtained?	Yes	No
	iv. Use of pre-existing / stored / left over samples	Yes	No
	v. Collection for banking / future research	Yes	No

	vi. Use of ionizing radiation / radio	-isotopes	Yes	No	
	If Yes, has Bhaba Atomic F (BARC) approval for Radioactive obtained?			No	
	vii. Use of infectious / bio-hazardou	us specimens	Yes	No	
	viii. Proper disposal of materials		Yes	No	
	ix. Will any sample collected from to abroad?	patients be sent	Yes	No	
	If Yes, justify with details of coll a. Is the proposal being submit from Health Ministry's Scree (HMSC) for International col	ted for clearance ening Committee laboration?		No	
	b. Sample will be sent abroad leading facility not available in India		ndia inaccessible	Facility available	hut not
	I defintly flot available in findia	1 demity in i	ndia inaccessible	being accessed.	
8.	Consent Writ	ten *	Oral	Audio-v	risual
	i. If written consent is obtained, tick	the included ele	ments listed below		
	Understandable language	Benefits		Contact informa	tion
	Statement that study involves research	Compensa participatio		Statement that of voluntary	consent is
	Sponsor of the study	Compensa related inju	tion for study Iry	Right to withdraw	W
	Purposes and procedures	Alternative	s to participation	Consent for futu biological mater	
	Risks & Discomforts	Confidentia	ality of records	Benefits if any o	on. Eg.
	* If written consent is not obtained,	then give reason	S.	Genetic basis fo	r drug devpt
	ii. Who will obtain consent PI /	Co-PI Re	esearch staff	Nurse / Counselor	Others
9.	Will any advertising be done for a subjects? (Posters, flyers, brochur – if so kindly attach a copy)		Yes	No	

10.	Risks & Benefits:			
	<ul> <li>i. Is the risk reasonable compared to the anticipated benefits to subjects / community / country</li> </ul>		Yes	No
	ii. Is there physical / social / psychological risk / discomfort		Yes	No
	If Yes, Minimal or no risk		More than Minimum risk	High risk
	iii. Is there a benefit to		Subject	Society
			Direct	Indirect
11.	Data Monitoring			
	<ul><li>i. Is there a data &amp; safety monitoring committee / board (DSMB)?</li></ul>		Yes	No
	ii. Is there a plan for reporting of adverse events?		Yes	No
	iii. If Yes reporting is done to Sponsor		Ethics Committee	DSMB
	iv. Is there a plan for interim analysis of data?		Yes	No
	v. Are there plans for storage and maintenance of all trial databases? <b>If Yes</b> , for how long.		Yes	No
12.	Is there compensation for participation?		Yes	No
	If Yes, Monetary In kind	Spe	cify amount & type:	
13.	Is there compensation for injury?  If Yes,		Yes	No
	By Sponsor By Investigator		By Insurance Company	By any other
14.	Do you have conflict of interest (financial / non-financial)		Yes	No
	If Yes, specify:			

15. Checklist for attached documents:		
Brief description of proposal	Copy of clinical trial protocol and/or questionnaire	
Curriculum Vitae of Investigators	Institutional Ethics Committee Clearance	
Patient information sheet	Institutional Animal Ethics Committee Clearance	
Consent form	CPCSEA clearance, if any.	
Investigator's brochure for recruiting subjects	HMSC / DCGI / DBT / BARC clearance if obtained	
Copy of advertisements / Information brochures		
Place:	Signature & Designation of PI	
Date:		
Please Note: This IEC application form should be forwarded by the Head of the Department to which the Principal Investigator is affiliated.		
Signature of the Head		
Department of		
Date:		